Allergy Therapeutics results nothing to sneeze at

By
0 mins. to read
Allergy Therapeutics results nothing to sneeze at
Master Investor Magazine

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed speciality pharmaceuticals company Allergy Therapeutics (LON:AGY) has reported a 10.6% increase in revenues for the six months ended 31st December. Operating profits before R&D costs improved by 27% and R&D spending declined relative to the same period of 2017.

CEO Manuel Llobet commented: “The Group has made a strong start to the financial year. Our ultra-short course products continue to drive good sales growth in a relatively flat market and the Group’s pre-R&D operating profit has increased as a result of investment into our commercial business last year and our focused sales and marketing strategy. 2019 will be a very important year for the Group and, in particular, our ultra-short course technology platform, with the start of the pivotal Phase III Grass MATA MPL trial for the US and Europe. With an increasing market share, a healthy balance sheet, and an exciting clinical pipeline nearing key value inflection points, we look to the future with confidence“.

The price of Allergy Therapeutics shares rose by 4.73% to 14.40p (as of 13:40 GMT).

Take part in our poll

Of the stocks covered by Master Investor in the weekly Small Cap Round Up, which ones do you hold?


The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.

Book your FREE tickets today using code: MIBLOG

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

YOUR FREE INVESTMENT MAG

Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.